Valuation Trading Multiples & Precedent Transactions: Monoclonal Antibody Drug Developers
Valuation benchmarks for Monoclonal Antibody Drug Developers. Access public trading comps, EV/EBITDA acquisition multiples, and private market data for pitch books and valuation analysis.
1.1 - Monoclonal Antibody Drug Developers Market Context & Valuation Drivers
Companies in this trading comparables group are public biopharmaceutical businesses that research, develop, manufacture, and commercialize therapeutic monoclonal antibodies and related biologics. They pursue oncology, immunology, and rare disease indications, generating revenue from marketed biologics, biosimilars, and licensing. They are comparable for valuation because they share R&D‑intensive models, cGMP biologics manufacturing, similar regulatory pathways, and pipeline risk/return profiles that define benchmarks in antibody therapeutics.
Typical capabilities include discovery and optimization of therapeutic monoclonal antibodies, development of antibody‑drug conjugates, and advancement of biosimilar antibodies to established reference products. Companies operate cGMP biologics manufacturing, scale cell culture production, and run preclinical and multi‑phase clinical trials. Many also produce recombinant proteins and vaccines, offer technology transfer or out‑licensing, and manage commercialization, market access, and pharmacovigilance for approved biologics across oncology, immunology, and hematology indications.
Primary customers include hospitals and health systems, specialty clinics and infusion centers, national procurement agencies, and biopharma partners for licensing or co‑development. Valuation drivers typically center on revenue growth from product launches, biologics gross margins and manufacturing yields, timing of clinical and regulatory milestones, market penetration and reimbursement durability, and pipeline quality measured by risk‑adjusted NPV and cash runway relative to R&D intensity.
2. Valuation Analysis: Public Trading Comps & Multiples for Monoclonal Antibody Drug Developers companies
2.1 - Public Peer Groups & Median Valuation Multiples for Monoclonal Antibody Drug Developers sector
Comparable group 1: Monoclonal Antibody Drug Developers
Hualan Biological Engineering
- Enterprise value: $●●●m
- Market Cap: $●●●m
- EV/Revenue: ●.●x
- EV/EBITDA: ●●.●x
- Description: Provider of research, development, production, and commercialization of human blood products, vaccines, monoclonal antibody, and genetic recombination biologics, achieving significant innovation and market impact in China's biopharmaceutical industry.
- Key Products:
- Plasma Products: High-quality human blood plasma for medical use
- Viral Vaccines: Development and production of vaccines for viral diseases
- Bacterial Vaccines: Production of vaccines for bacterial infections
- Monoclonal Antibodies: Research and development of therapeutic monoclonal antibodies
- Genetic Recombination Biologics: Production and commercialization of genetically engineered biologics
Sinocelltech Group
- Enterprise value: $●●●m
- Market Cap: $●●●m
- EV/Revenue: ●.●x
- EV/EBITDA: ●●.●x
- Description: Provider of biotechnology solutions specializing in the development and production of recombinant proteins, monoclonal antibodies, and vaccines with applications in various therapeutic areas including oncology, autoimmune diseases, and infectious diseases.
- Key Products:
- Recombinant Proteins: Biopharmaceutical products for therapeutic interventions across various diseases
- Monoclonal Antibodies: Targeted therapies for autoimmune and oncological conditions
- Vaccines: Provides immunity against infectious agents
- Ripertamab: Anti-CD20 monoclonal antibody approved by China's NMPA
- SCT200: Humanized anti-EGFR monoclonal antibody for cancer treatment